BIO-TECHNE earnings release, August 12, 2026
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
Minneapolis/August 12, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026.
Fourth Quarter FY2026 Highlights
● Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million. Full year organic and reported revenue remained flat at $1.2 billion.
● GAAP EPS increased to $0.35 from $(0.11) one year ago. Delivered adjusted EPS was $0.52, down from $0.53 one year ago. Full year GAAP EPS increased to $1.16 versus $0.46 one year ago. Full year adjusted EPS was $1.93, up from $1.92 one year ago.
● As previously announced on June 25, 2026, Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion.
“Bio-Techne ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research and diagnostic workflows,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “We continue to make progress toward completing Bio-Techne’s acquisition by Merck KGaA, Darmstadt, Germany, and look forward to the opportunities this transaction is expected to create for our customers and employees.”
Conference Call
In light of the announced transaction with Merck KGaA, Darmstadt, Germany, Bio-Techne is no longer holding investor conference calls for quarterly results.
Fourth Quarter Fiscal 2026
Revenue
Net sales for the fourth quarter increased 1% to $321.2 million. Organic growth increased 3% compared to the prior year. Non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2% and foreign currency exchange did not have a material impact.
GAAP Earnings Results
GAAP EPS was $0.35 per diluted share versus $(0.11) in the same quarter last year. GAAP operating income for the fourth quarter of fiscal 2026 was
$74.3 million compared to an operating loss of $23.9 million in the fourth quarter of fiscal 2025. GAAP operating margin was 23.1% compared to (7.5)% in the fourth quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year.
Non-GAAP Earnings Results
Adjusted EPS decreased to $0.52 per diluted share compared to $0.53 in the same quarter last year. Adjusted operating income increased to $103.4 million in the fourth quarter of fiscal 2026 compared to $101.3 million in the fourth quarter of fiscal 2025. Adjusted operating margin was 32.2% for the fourth quarter of fiscal 2026 compared to 32.0% in the fourth quarter of fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture, partially offset by unfavorable product mix.
Full Year Fiscal 2026
Revenue
Net sales for the full year fiscal 2026 remained flat from the prior year at $1.2 billion. Organic revenue remained flat from the prior year. Foreign currency exchange had a favorable impact of 2% and a business held-for-sale had an unfavorable impact of 2%.
GAAP Earnings Results
GAAP EPS was $1.16 per diluted share, compared to $0.46 last fiscal year. GAAP operating income for full year fiscal 2026 increased 146% to $251.9 million, compared to $102.3 million in the full year fiscal 2025. GAAP operating margin was 20.7% compared to 8.4% in the full year fiscal 2025. GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year, a non-recurring arbitration award in the prior year, and a recovery of assets held-for-sale.
Non-GAAP Earnings Results
Adjusted EPS increased to $1.93 per diluted share, compared to $1.92 last fiscal year. Adjusted operating income for fiscal 2026 increased 1% to $386.1 million, compared to $383.6 million for fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture.
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the Company’s business segments, as highlighted below.
Protein Sciences Segment
The Company’s Protein Sciences segment is one of the world’s leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The
Protein Sciences segment’s fourth quarter fiscal 2026 net sales were $231.2 million, an increase of 2% from $226.5 million in the fourth quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment’s operating results for both periods presented. Organic revenue increased 1% for the fourth quarter of fiscal 2026, with foreign currency exchange having a favorable impact of 1%. The Protein Sciences segment’s operating margin decreased to 42.0% in the fourth quarter of fiscal 2026 compared to 43.6% in the fourth quarter of fiscal 2025. The segment’s operating margin decreased primarily due to unfavorable volume and product mix.
Protein Sciences segment’s full year fiscal 2026 net sales were $874.6 million, an increase of 1% from $870.2 million for full year fiscal 2025. Organic revenue for the segment decreased 1% for the fiscal year, with foreign currency exchange having a favorable impact of
2%. Protein Sciences segment’s operating margin was 41.1% in fiscal 2026 compared to 42.6% in fiscal 2025. The segment’s operating margin was impacted by unfavorable volume and product mix.
Diagnostics and Spatial Biology Segment
... (truncated) products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market.
The Diagnostics and Spatial Biology segment’s fourth quarter fiscal 2026 net sales remained flat at $90.1 million, as compared to $89.7 million in the fourth quarter of fiscal 2025. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment’s fiscal 2026 operating results. Organic revenue increased 8% for the fourth quarter of fiscal 2026, with foreign exchange not having a material impact. The held-for-sale business had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment’s operating margin increased to 11.2% in the fourth quarter of fiscal 2026 compared to 6.0% in the fourth quarter of fiscal 2025.
The segment’s operating margin was favorably impacted by the Exosome Diagnostics divestiture, favorable volume growth, and ongoing profitability initiatives.
The Diagnostics and Spatial Biology segment’s full year fiscal 2026 net sales were $336.4 million, a decrease of 3% from $346.3 million for the full year fiscal 2025. Organic growth for the segment was 4%, with foreign currency exchange having a favorable impact of 1%. A business held-for-sale had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment’s operating margin was 11.2% in fiscal 2026 compared to 6.2% in fiscal 2025. The segment’s operating margin was impacted by the divestiture of Exosome Diagnostics, favorable volume growth, and ongoing profitability initiatives.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at
LinkedIn,
X, or
YouTube.
Forward Looking Statements:
Financial statements
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – June 30, – 2026 | Quarter Ended – June 30, – 2025 | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | ||
|---|---|---|---|---|---|
| Net sales | 321,191 | 316,964 | 1,215,039 | 1,219,635 | |
| Cost of sales | 109,797 | 118,152 | 415,968 | 429,363 | |
| Gross margin | 211,394 | 198,812 | 799,071 | 790,272 | |
| Operating expenses: | Selling, general and administrative | 113,172 | 196,640 | 452,415 | 588,521 |
| Operating expenses: | Research and development | 23,945 | 26,032 | 94,766 | 99,496 |
| Operating expenses: | Total operating expenses | 137,117 | 222,672 | 547,181 | 688,017 |
| Operating expenses: | Operating income | 74,277 | -23,860 | 251,890 | 102,255 |
| Operating expenses: | Other income (expense) | -3,596 | 1,001 | -11,210 | -3,792 |
| Operating expenses: | Earnings before income taxes | 70,681 | -22,859 | 240,680 | 98,463 |
| Operating expenses: | Income taxes | 16,059 | -5,182 | 58,818 | 25,063 |
| Operating expenses: | Net earnings | 54,622 | -17,677 | 181,862 | 73,400 |
| Earnings per share: | Basic | 0.35 | -0.11 | 1.17 | 0.47 |
| Earnings per share: | Diluted | 0.35 | -0.11 | 1.16 | 0.46 |
| Weighted average common shares outstanding: | Basic | 156,090 | 154,913 | 155,963 | 157,521 |
| Weighted average common shares outstanding: | Diluted | 157,025 | 155,757 | 157,009 | 159,717 |
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – June 30, – 2026 | Quarter Ended – June 30, – 2025 | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | ||
|---|---|---|---|---|---|
| Total consolidated net sales | 321,191 | 316,964 | 1,215,039 | 1,219,635 | |
| Business held-for-sale(1) | 5,439 | 4,152 | |||
| Revenue from recurring operations | 321,191 | 316,964 | 1,209,600 | 1,215,483 | |
| Gross margin - GAAP | 211,394 | 198,812 | 799,071 | 790,272 | |
| Gross margin percentage - GAAP | 65.8% | 62.7 | 65.8% | 64.8 | |
| Identified adjustments: | Costs recognized upon sale of acquired inventory | $— | 197 | $— | 751 |
| Identified adjustments: | Amortization of intangibles | 9,422 | 10,569 | 37,799 | 44,035 |
| Identified adjustments: | Stock-based compensation, inclusive of employer taxes | 282 | 288 | 1,534 | 1,298 |
| Identified adjustments: | Restructuring and restructuring-related costs | 1,049 | 12,141 | 5,805 | 20,094 |
| Identified adjustments: | Impact of business held-for-sale(1) | -2,581 | -147 | ||
| Identified adjustments: | Adjusted gross margin | 222,147 | 222,007 | 841,628 | 856,303 |
| Identified adjustments: | Adjusted gross margin percentage(2) | 69.2% | 70 | 69.6% | 70.4 |
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – June 30, – 2026 | Quarter Ended – June 30, – 2025 | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | |
|---|---|---|---|---|
| Net earnings | 54,622 | -17,677 | 181,862 | 73,400 |
| Net interest expense (income) | 750 | 1,593 | 5,405 | 4,623 |
| Depreciation and amortization | 24,169 | 27,111 | 97,359 | 109,903 |
| Income taxes | 16,059 | -5,182 | 58,818 | 25,063 |
| EBITDA | 95,600 | 5,845 | 343,444 | 212,989 |
| Amortization of Wilson Wolf intangible assets | 2,490 | 2,490 | 9,959 | 9,959 |
| Acquisition related expenses and other | 1,782 | 4,010 | 8,570 | 13,489 |
| Certain litigation charges | 143 | 1,220 | 5,513 | 41,827 |
| Stock-based compensation, inclusive of employer taxes | 5,375 | 4,653 | 42,637 | 42,158 |
| Restructuring and restructuring-related costs | 6,858 | 13,205 | 21,059 | 28,231 |
| Investment loss and other non-operating loss | 3,695 | 5,009 | ||
| Impairment (Recovery) of assets held-for-sale | 84,157 | -6,789 | 80,503 | |
| Impact of business held-for-sale(1) | 2,573 | 479 | ||
| Adjusted EBITDA | 115,943 | 115,580 | 431,975 | 429,635 |
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – June 30, – 2026 | Quarter Ended – June 30, – 2025 | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | ||
|---|---|---|---|---|---|
| Net earnings before taxes - GAAP | 70,681 | -22,859 | 240,680 | 98,463 | |
| Identified adjustments: | Amortization of intangibles | 15,070 | 18,185 | 61,181 | 75,321 |
| Identified adjustments: | Amortization of Wilson Wolf intangible assets | 2,490 | 2,490 | 9,959 | 9,959 |
| Identified adjustments: | Acquisition related expenses and other | 1,782 | 4,010 | 8,570 | 13,489 |
| Identified adjustments: | Certain litigation charges | 143 | 1,220 | 5,513 | 41,827 |
| Identified adjustments: | Stock-based compensation, inclusive of employer taxes | 5,375 | 4,653 | 42,637 | 42,158 |
| Identified adjustments: | Restructuring and restructuring-related costs | 6,858 | 13,205 | 21,059 | 28,231 |
| Identified adjustments: | Investment loss and other non-operating loss | 3,695 | 5,009 | ||
| Identified adjustments: | Impairment (Recovery) of assets held-for-sale | 84,157 | -6,789 | 80,503 | |
| Identified adjustments: | Impact of business held-for-sale(1) | 2,573 | 479 | ||
| Identified adjustments: | Net earnings before taxes - Adjusted | 106,094 | 105,061 | 390,392 | 390,430 |
| Identified adjustments: | Non-GAAP tax rate | 22.3% | 21.5% | 22.3% | 21.5% |
| Identified adjustments: | Non-GAAP tax expense | 23,658 | 22,589 | 87,057 | 83,973 |
| Identified adjustments: | Non-GAAP adjusted net earnings | 82,436 | 82,472 | 303,335 | 306,457 |
| Identified adjustments: | Earnings per share - diluted - Adjusted | 0.52 | 0.53 | 1.93 | 1.92 |
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – June 30, – 2026 | Quarter Ended – June 30, – 2025 | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | |
|---|---|---|---|---|
| Protein Sciences segment operating income | 97,073 | 98,790 | 359,401 | 370,353 |
| Diagnostics and Spatial Biology segment operating income | 10,069 | 5,384 | 37,698 | 21,324 |
| Segment operating income | 107,142 | 104,174 | 397,099 | 391,677 |
| Corporate general, selling, and administrative | -3,783 | -2,847 | -11,049 | -8,088 |
| Adjusted operating income | 103,359 | 101,327 | 386,050 | 383,589 |
| Amortization of intangibles | -15,070 | -18,185 | -61,181 | -75,321 |
| Acquisition related expenses and other | -1,636 | -3,767 | -7,986 | -12,815 |
| Certain litigation charges | -143 | -1,220 | -5,513 | -41,827 |
Balance Sheet
(Unaudited)
| June 30, – 2026 | June 30, – 2025 | ||
|---|---|---|---|
| ASSETS | Cash and equivalents | 264,712 | 162,186 |
| ASSETS | Accounts receivable, net | 216,585 | 206,876 |
| ASSETS | Inventories | 195,744 | 189,446 |
| ASSETS | Current assets held-for-sale | 12,332 | |
| ASSETS | Other current assets | 67,360 | 37,460 |
| ASSETS | Total current assets | 744,401 | 608,300 |
| ASSETS | Property and equipment, net | 231,836 | 245,719 |
| ASSETS | Right of use assets | 67,333 | 73,399 |
| ASSETS | Goodwill and intangible assets, net | 1,278,820 | 1,346,534 |
| ASSETS | Other assets | 264,336 | 283,916 |
| ASSETS | Total assets | 2,586,726 | 2,557,868 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Accounts payable and accrued expenses | 105,075 | 116,765 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Contract liabilities | 36,072 | 32,571 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Income taxes payable | 3,593 | 10,770 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Operating lease liabilities - current | 14,935 | 14,098 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Other current liabilities | 4,025 | 1,645 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Total current liabilities | 163,700 | 175,849 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Deferred income taxes | 19,308 | 6,169 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Long-term debt obligations | 200,000 | 346,000 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Operating lease liabilities | 74,152 | 83,960 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Other long-term liabilities | 21,345 | 27,082 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Stockholders' equity | 2,108,221 | 1,918,808 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Total liabilities and stockholders' equity | 2,586,726 | 2,557,868 |
Cash Flow
(Unaudited)
| Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 | ||
|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | Net earnings | 181,862 | 73,400 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Depreciation and amortization | 97,359 | 109,903 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Costs recognized on sale of acquired inventory | 751 | |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Deferred income taxes | 13,196 | -51,107 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Stock-based compensation expense | 41,365 | 40,833 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | (Gain) Loss on equity method investment | -887 | -938 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Asset impairment restructuring | 3,914 | 21,312 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Recovery of assets held-for-sale | -6,789 | 80,503 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Other operating activities | -37,947 | 12,899 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Net cash provided by (used in) operating activities | 292,073 | 287,556 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Proceeds from sale of available-for-sale investments | 1,085 | |
| CASH FLOWS FROM INVESTING ACTIVITIES | Additions to property and equipment | -28,850 | -31,006 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Distributions from Wilson Wolf | 6,043 | 7,291 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Investment in Spear Bio | -15,000 | |
| CASH FLOWS FROM INVESTING ACTIVITIES | Proceeds from sale of assets held-for-sale | 4,617 | 2,447 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Net cash provided by (used in) investing activities | -18,190 | -35,183 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Cash dividends | -49,916 | -50,391 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Proceeds from stock option exercises | 80,618 | 51,739 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Long-term debt activity, net | -146,000 | 27,000 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Repurchases of common stock | -41,675 | -275,731 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Taxes paid on RSUs and net share settlements | -12,141 | -6,522 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Net cash provided by (used in) financing activities | -169,114 | -253,905 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Effect of exchange rate changes on cash and cash equivalents | -2,243 | 11,927 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Net increase (decrease) in cash and cash equivalents | 102,526 | 10,395 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Cash and cash equivalents at beginning of period | 162,186 | 151,791 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Cash and cash equivalents at end of period | 264,712 | 162,186 |
Full release
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements use words and variations of words, such as “will,” “plan,” “continue,” “believe,” “outlook,” “expect,” and “predict.” These statements are made as of the date of this press release, are based on current expectations of future events, and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the Company’s control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. These risks, uncertainties, and other factors include, without limitation: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company’s customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning these risks, uncertainties, and other factors, see the section titled “Risk Factors” in the Company’s most recent annual report on Form 10-K as filed with the Securities and Exchange Commission. We undertake and we expressly disclaim any obligation to update or revise any forward-looking statements due to new information, changed assumptions, or future events, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.
Non-GAAP Financial Measures:
The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). This press release contains financial measures that have not been calculated in accordance with GAAP. These non-GAAP measures include:
These non-GAAP measures should not be considered in isolation or as a substitute for any measure derived in accordance with GAAP and may also be inconsistent with similar measures presented by other companies. Reconciliations of these measures to the applicable most closely comparable GAAP measures, and reasons for the Company’s use of these measures, are presented in the attached pages.
David.Clair@bio-techne.com
612-656-4416